Cholelithiasis News and Research

RSS

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Obesity drives shared genetic risk behind many chronic disease combinations

The study uncovers obesity's genetic links to chronic diseases, offering insights into multimorbidity and the potential for targeted health interventions.

9 Feb 2026

Scientists uncover new obesity genes that reshape understanding of weight and disease risk

Researchers identified five previously unknown genes linked to obesity by analyzing rare protein-truncating variants across six ancestries. The study reveals how rare and common genetic factors combine to influence BMI and related diseases like diabetes and heart failure.

2 Nov 2025

Targeting PCSK9 and APOA4 for the treatment of TMAO-induced cholelithiasis

Cholesterol synthesis and gallstone formation are promoted by trimethylamine-N-oxide (TMAO), a derivative of trimethylamine, which is a metabolite of gut microbiota.

25 Mar 2025

Researchers uncover 195 genetic risk factors driving women’s reproductive diseases

Scientists identified 195 genetic risk loci across 42 female reproductive health conditions, revealing shared genetic pathways and developing a polygenic risk score for intrahepatic cholestasis of pregnancy (ICP). These findings pave the way for personalized reproductive healthcare and targeted treatments based on genetic risk.

12 Mar 2025

Tirzepatide significantly reduces weight and diabetes risk in patients with obesity and prediabetes

Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with lasting benefits and manageable side effects.

14 Nov 2024

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.

12 Sep 2024

Tirzepatide outperforms semaglutide in weight loss for overweight and obese adults

Tirzepatide leads to significantly greater weight loss than semaglutide in overweight or obese adults, with no significant difference in gastrointestinal adverse effects.

10 Jul 2024

GLP-1 receptor agonists effective for weight loss in obesity without diabetes

The benefit-harm balance of initiating Glucagon-like Peptide-1 (GLP-1) receptor agonists (RAs) versus a placebo intervention.

29 May 2024

Study evaluates the use of tirzepatide in overweight/obese adults with type 1 diabetes

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the use of tirzepatide in overweight/obese adults with type 1 diabetes.

22 Mar 2024

Study sheds light on the complex relationship between serum lipids, lipid-modifying targets, and cholelithiasis

A new study published in the journal Gut has shed light on the complex relationship between serum lipids, lipid-modifying targets, and cholelithiasis, a common condition characterized by the formation of gallstones.

27 Nov 2023

Could the microbiome hold the key to diagnosing and treating biliary tract cancer?

A recent study in "Microorganisms" delves into the relationship between the microbiome and biliary tract cancer, revealing distinct microbial compositions in patients compared to healthy individuals. This research highlights potential diagnostic biomarkers and suggests that altering gut microbial composition might enhance responses to cancer immunotherapy.

24 Oct 2023

How does the gut microbiome affect muscle strength?

Researchers use fecal microbiome transplantation in mouse models to examine the role of gut microbiota in determining muscle strength.

14 Mar 2023

Metabolomic study of genetic regulation of biochemical individuality

Researchers systematically investigated the genetic makeup of nearly 20,000 women and men in terms of >900 metabolites.

15 Nov 2022

Scientific review highlights the impact of coffee on digestive organs

A new scientific review, published in Nutrients, highlights coffee's effects on digestion and the gut, and its impact on organs involved in digestion.

19 Jan 2022

Gallstones, statins increase risk of acute pancreatitis, shows study

Idiopathic pancreatitis is often caused by small gallstones that are difficult to observe prior to surgery, shows a study from the University of Eastern Finland. Small gallstones were found in surgery from two out of three idiopathic pancreatitis patients.

8 Dec 2015

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

16 Dec 2014

Researchers recommend laparoscopic surgical removal of gallbladder for pediatric patients

A recent study conducted by Mayo Clinic researchers recommends laparoscopic cholecystectomies (surgical removal of the gallbladder) for pediatric patients suffering from gallstones and other gallbladder diseases.

8 Aug 2014

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for Somatuline Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

1 Jul 2014